Physiogenex
  • About Us
    • Company overview
    • Management Team
    • Our values
    • Facilities
    • Partners
  • CRO Services
    • Obesity – Insulin Resistance – Diabetes
    • GLP-1 Expertise
    • NASH – Fibrosis
    • Dyslipidaemia Atherosclerosis
    • Diabetic Nephropathy
    • Immunometabolism
    • Nutraceuticals
    • Covid-19
  • Capabilities
    • In vivo metabolic studies
    • Ex vivo metabolic assays
    • Biochemical assays and histology analysis
    • Biological samples library
  • Consulting
  • Publications
  • News
  • careers
    • Spontaneous Application
    • Careers at Physiogenex
  • Contact us
Select Page
AASLD Liver Meeting (November 8-12) in Boston, Massachusetts

AASLD Liver Meeting (November 8-12) in Boston, Massachusetts

by François Briand | Nov 27, 2019 | 2019

Physiogenex presented a poster on Monday, November 11th, 2019 at the AASLD Liver Meeting (November 8-12) in Boston, Massachusetts. Dr François Briand, our Director of Research and Development, attented the Poster Session held at the Hynes Convention Center and...
Physiogenex inaugurates its new premises near Toulouse

Physiogenex inaugurates its new premises near Toulouse

by François Briand | Nov 7, 2019 | 2019

ENGLISH VERSION Brand new facilities for Physiogenex! In September, we celebrated the inauguration of our new laboratories near Toulouse, as well as our 15th anniversary. With more than 1000 m² dedicated to the research and development of new therapeutic strategies...
Obesity Week 2019 (November 3-7) in Las Vegas, Nevada.

Obesity Week 2019 (November 3-7) in Las Vegas, Nevada.

by François Briand | Nov 4, 2019 | 2019

Physiogenex will be presenting a poster on Tuesday, November 5th, 2019 from 12pm to 1:30pm at the Obesity Week 2019 (November 3-7) in Las Vegas. Dr François Briand, our Director of Research and Development, will be at the Poster Session at Mandalay Bay South...
79th American Diabetes Association Scientific Sessions (June 7-11, 2019) in San Francisco, California.

79th American Diabetes Association Scientific Sessions (June 7-11, 2019) in San Francisco, California.

by François Briand | May 31, 2019 | 2019

Physiogenex will be presenting a poster on Monday, June 10, 2019 12:00 PM – 01:00 PM at the American Diabetes Association’s 79th Scientific Sessions on June 7-11 in San Francisco. Dr. François Briand, our Director of Research and Business Development, will be present...
87th EAS Congress (May 26-29, 2019) in Maastricht, Netherlands

87th EAS Congress (May 26-29, 2019) in Maastricht, Netherlands

by François Briand | May 17, 2019 | 2019

Physiogenex will attend the 2019 EAS Congress on May 26-29, 2019 in Maastricht. Dr. François Briand, our Director of Research and Business Development, will be present at this event. He will be happy to discuss with you about your preclinical atherosclerosis projects....
3rd Annual NASH Summit (April 22-25, 2019) in Boston, Massachusetts, USA.

3rd Annual NASH Summit (April 22-25, 2019) in Boston, Massachusetts, USA.

by François Briand | Apr 17, 2019 | 2019

Physiogenex will attend the 2019 edition of the NASH Annual Summit on April 23 and 24th in Boston. The NASH Summit in Boston is one a leading industry forum for advancing the development of successful NASH therapeutics. This event is focused on discovery through to...
« Older Entries

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH/fibrosis, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications. For > 15 years, we have been evaluating the drugs’ efficacy of our clients using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated with our numerous co-publications with our industry partners.

For more information on our company and offers, please download our Corporate Presentation.

Menu

  • CRO Services
  • Consulting
  • Publications
  • News
  • Careers

Services

  • Obesity – Diabetes
  • NASH Preclinical
  • Dyslipidaemia Atherosclerosis
  • Diabetic Nephropathy
  • Nutraceuticals

Useful Menu

  • Accueil
  • Contact us
  • Site map
  • Legal mentions
  • Privacy Policy

Contact

PHYSIOGENEX S.A.S.

Address : 280 rue de l’Hers, ZAC de la Masquère, 31750 Escalquens – France
Phone : +33532097980

For general inquiries, please contact us here.

  • Twitter
  • RSS
Copyright © PHYSIOGENEX
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT